COMPARISON OF DIFFERENT REMISSION INDICES IN PATIENTS WITH PSORIATIC ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM PHASE 3 TOFACITINIB STUDIES

被引：0
|
作者：
Schneeberger, E. [1 ]
Citera, G. [1 ]
Nash, P. [2 ]
Smolen, J. S. [3 ]
Mease, P. J. [4 ,5 ]
Soriano, E. [6 ]
Helling, C. [7 ]
Szumski, A. E. [8 ]
Mundayat, R. [9 ]
Graham, D. [10 ]
Ponce de Leon, D. [11 ]
机构：
[1] Inst Rehabil Psicofis, Buenos Aires, DF, Argentina
[2] Griffith Univ, Brisbane, Qld, Australia
[3] Med Univ Vienna, Vienna, Austria
[4] Swedish Med Ctr, Seattle, WA USA
[5] Univ Washington, Seattle, WA 98195 USA
[6] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[7] Pfizer Inc, Buenos Aires, DF, Argentina
[8] Pfizer Inc, Collegeville, PA USA
[9] Pfizer Inc, New York, NY USA
[10] Pfizer Inc, Groton, CT 06340 USA
[11] Pfizer Inc, Lima, Peru
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.948
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0831
引用
收藏
页码：1716 / 1717
页数：2
相关论文
共 50 条
  • [31] Comparison of Composite Indices for Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib: A Post-Hoc Analysis from SELECT-PsA 1
    Smolen, Josef
    Lubrano, Ennio
    Kishimoto, Mitsumasa
    Balanescu, Andra R.
    Strand, Vibeke
    Gao, Tianming
    Vranich, Nancy
    Lippe, Ralph
    Tillett, William
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3790 - 3792
  • [32] COMPARISON OF COMPOSITE INDICES FOR DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: A POST-HOC ANALYSIS FROM SELECT-PSA 1
    Smolen, J. S.
    Lubrano, E.
    Kishimoto, M.
    Balanescu, A.
    Strand, V.
    Gao, T.
    Vranich, N.
    Lippe, R.
    Tillett, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 824 - 824
  • [33] Impact of Sociodemographic Factors on Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 2/3/3b/4 Studies
    Wright, Grace
    Mysler, Eduardo
    Roberts, Kevin
    Sweet, Lindsay
    Shelbaya, Ahmed
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4172 - 4175
  • [34] EFFICACY OF ADALIMUMAB AND TOFACITINIB IN RHEUMATOID ARTHRITIS: POST-HOC ANALYSES FROM A PHASE 3 STUDY
    van Vollenhoven, R.
    Cohen, S.
    Mendelsohn, A.
    Bananis, E.
    Fan, H.
    Takiya, L.
    Fleischmann, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 1042 - 1042
  • [35] Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials
    Bessette, Louis
    Dougados, Maxime
    Mysler, Eduardo
    Genovese, Mark
    Kinch, Cassandra
    Kwok, Kenneth
    Lukic, Tatjana
    Girard, Tanya
    Landry, Pierre-Alexandre
    van Vollenhoven, Ronald
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [36] Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients With Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials
    Bessette, Louis
    Dougados, Maxime
    Mysler, Eduardo
    Genovese, Mark
    Kinch, Cassandra
    Kwok, Kenneth
    Lukic, Tatjana
    Girard, Tanya
    Landry, Pierre-Alexandre
    van Vollenhoven, Ronald
    JOURNAL OF RHEUMATOLOGY, 2020, 47 (07) : 1106 - 1107
  • [37] Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression And/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials
    Citera, Gustavo
    Jain, Rakesh
    Irazoque, Fedra
    Guzman, Renato
    Madariaga, Hugo
    Gruben, David
    Wang, Lisy
    Stockert, Lori
    Hsu, Ming-Ann
    Santana, Karina
    Ebrahim, Abbas
    Ponce de Leon, Dario
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [38] TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INDICATIVE OF DEPRESSION AND/OR ANXIETY: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 CLINICAL TRIALS
    Citera, G.
    Jain, R.
    Irazoque-Palazuelos, F.
    Guzman, R.
    Madariaga, H.
    Gruben, D. C.
    Wang, L.
    Stockert, L.
    Hsu, M. A.
    Santana, K.
    Ebrahim, A.
    Ponce de Leon, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 314 - 315
  • [39] Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis
    Gladman, Dafna
    Nash, Peter
    Mease, Philip J.
    FitzGerald, Oliver
    Masri, Karim R.
    Duench, Stephanie
    Jane Cadatal, Mary
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2798 - 2801
  • [40] Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis: Results from two phase 3 studies
    Strand, Vibeke
    de Vlam, Kurt
    Covarrubias-Cobos, Jose
    Mease, Philip
    Gladman, Dafna
    Hendrikx, Thijs
    Graham, Daniela
    Wu, Joseph
    Chen, Linda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB109 - AB109
12345